ASO Author Reflections: Can We Predict an Unsalvageable Recurrence Following Colorectal Liver Metastasectomy?

  • Masayuki Okuno
  • Claudius Conrad
ASO Author Reflections



Masayuki Okuno and Claudius Conrad have no conflicts of interest to disclose.


  1. 1.
    Oba M, Hasegawa K, Matsuyama Y, et al. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol 2014;21(6):1817–1824.CrossRefGoogle Scholar
  2. 2.
    Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–626; discussion 626–617.Google Scholar
  3. 3.
    Mise Y, Zimmitti G, Shindoh J, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(3):834–842.CrossRefGoogle Scholar
  4. 4.
    Denbo JW, Yamashita S, Passot G, et al. RAS mutation is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg. 2017;21(1):68–77.CrossRefGoogle Scholar
  5. 5.
    Okuno M, Goumard C, Kopetz S, et al. RAS mutation is associated with unsalvageable recurrence following hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2018;25(8):2457–2466.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations